Advertisement

Biogen Idec (Nasdaq: BIIB), a biotechnology company best known for its blockbuster multiple sclerosis treatments, has announced that a European regulatory panel has given a positive recommendation to a new self-administered form of its Avonex MS drug. The committee’s positive opinion means it is very likely that EU regulators will approve the new so-called “Avonex Pen,” within 75 days.

Weston-based Biogen said the Avonex Pen has also been authorized by Canadian regulators.

SOURCE

Advertisement
Advertisement